Paul E Gray1,2, Tracey A O'Brien2,3, Mayura Wagle4,5, Stuart G Tangye4,5, Umaimainthan Palendira4,5, Tony Roscioli6,7, Sharon Choo8, Rosemary Sutton9, John B Ziegler1,2, Katie Frith10,11. 1. Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, Australia. 2. School of Women's and Children's Health, University of New South Wales, Sydney, Australia. 3. Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia. 4. Immunology and Immunodeficiency Group, Immunology Research Program, Garvan Institute of Medical Research, Darlinghurst, Australia. 5. St Vincent's Clinical School, University of New South Wales, Sydney, Australia. 6. Department of Medical Genetics, Sydney Children's Hospital, Randwick, Australia. 7. Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, Australia. 8. Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia. 9. Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, Australia. 10. Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, Australia. frith.katie@gmail.com. 11. School of Women's and Children's Health, University of New South Wales, Sydney, Australia. frith.katie@gmail.com.
Abstract
UNLABELLED: Vasculitis occurs rarely in association with X-linked lymphoproliferative disease (XLP). There are four published cases of non-EBV XLP-associated cerebral vasculitis reported, none of whom have survived without major cognitive impairment. CASE: A 9-year old boy initially presented aged 5 years with a restrictive joint disease. He subsequently developed dysgammaglobulinemia, episodic severe pneumonitis, aplastic anaemia, gastritis and cerebral vasculitis. A diagnosis of XLP was made, based on flow cytometric analysis and the identification of a novel mutation in SH2D1A, c.96G>C. No peripheral blood lymphocyte clonal proliferation was identified and he was EBV negative, although human herpes virus-7 (HHV7) was detected repeatedly in his cerebrospinal fluid. He underwent a reduced intensity unrelated umbilical cord blood transplant, but failed to engraft. A second 5/6 matched cord gave 100 % donor engraftment. Complications included BK virus-associated haemorrhagic cystitis, a possible NK-cell mediated immune reconstitution syndrome and post-transplant anti-glomerular basement membrane disease, the latter treated with cyclophosphamide and rituximab. At +450 days post-transplant he is in remission from his vasculitis and anti-glomerular basement membrane disease, and HHV-7 has remained undetectable. CONCLUSION: This is the second published description of joint disease in XLP, and only the fourth case of non-EBV associated cerebral vasculitis in XLP, as well as being the first to be successfully treated for this manifestation. This case raises specific questions about vasculitis in XLP, in particular the potential relevance of HHV-7 to the pathogenesis.
UNLABELLED: Vasculitis occurs rarely in association with X-linked lymphoproliferative disease (XLP). There are four published cases of non-EBV XLP-associated cerebral vasculitis reported, none of whom have survived without major cognitive impairment. CASE: A 9-year old boy initially presented aged 5 years with a restrictive joint disease. He subsequently developed dysgammaglobulinemia, episodic severe pneumonitis, aplastic anaemia, gastritis and cerebral vasculitis. A diagnosis of XLP was made, based on flow cytometric analysis and the identification of a novel mutation in SH2D1A, c.96G>C. No peripheral blood lymphocyte clonal proliferation was identified and he was EBV negative, although human herpes virus-7 (HHV7) was detected repeatedly in his cerebrospinal fluid. He underwent a reduced intensity unrelated umbilical cord blood transplant, but failed to engraft. A second 5/6 matched cord gave 100 % donor engraftment. Complications included BK virus-associated haemorrhagic cystitis, a possible NK-cell mediated immune reconstitution syndrome and post-transplant anti-glomerular basement membrane disease, the latter treated with cyclophosphamide and rituximab. At +450 days post-transplant he is in remission from his vasculitis and anti-glomerular basement membrane disease, and HHV-7 has remained undetectable. CONCLUSION: This is the second published description of joint disease in XLP, and only the fourth case of non-EBV associated cerebral vasculitis in XLP, as well as being the first to be successfully treated for this manifestation. This case raises specific questions about vasculitis in XLP, in particular the potential relevance of HHV-7 to the pathogenesis.
Authors: Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar Journal: Blood Date: 2010-10-06 Impact factor: 22.113
Authors: L Yin; V Ferrand; M F Lavoué; D Hayoz; N Philippe; G Souillet; M Seri; R Giacchino; E Castagnola; S Hodgson; B S Sylla; G Romeo Journal: Hum Genet Date: 1999-11 Impact factor: 4.132
Authors: Maria C Sirianni; Massimo Campagna; Donato Scaramuzzi; Maurizio Carbonari; Elena Toschi; Ilaria Bacigalupo; Paolo Monini; Barbara Ensoli Journal: Ann N Y Acad Sci Date: 2007-01 Impact factor: 5.691
Authors: M Morra; M Simarro-Grande; M Martin; A S Chen; A Lanyi; O Silander; S Calpe; J Davis; T Pawson; M J Eck; J Sumegi; P Engel; S C Li; C Terhorst Journal: J Biol Chem Date: 2001-07-26 Impact factor: 5.157
Authors: J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Bethany A Pillay; Danielle T Avery; Joanne M Smart; Theresa Cole; Sharon Choo; Damien Chan; Paul E Gray; Katie Frith; Richard Mitchell; Tri Giang Phan; Melanie Wong; Dianne E Campbell; Peter Hsu; John B Ziegler; Jane Peake; Frank Alvaro; Capucine Picard; Jacinta Bustamante; Benedicte Neven; Andrew J Cant; Gulbu Uzel; Peter D Arkwright; Jean-Laurent Casanova; Helen C Su; Alexandra F Freeman; Nirali Shah; Dennis D Hickstein; Stuart G Tangye; Cindy S Ma Journal: JCI Insight Date: 2019-04-25
Authors: Paul Edgar Gray; Bella Shadur; Susan Russell; Richard Mitchell; Michael Buckley; Kerri Gallagher; Ian Andrews; Kevin Thia; Joseph A Trapani; Edwin Philip Kirk; Ilia Voskoboinik Journal: Front Immunol Date: 2017-08-09 Impact factor: 7.561
Authors: Jolanda Steininger; Raphael Rossmanith; Christoph B Geier; Alexander Leiss-Piller; Lukas Thonhauser; Simone Weiss; Johannes A Hainfellner; Michael Freilinger; Wolfgang M Schmidt; Martha M Eibl; Hermann M Wolf Journal: Front Immunol Date: 2021-12-20 Impact factor: 7.561
Authors: Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert Journal: Cells Date: 2022-07-11 Impact factor: 7.666
Authors: Paul E Gray; Hugh McCarthy; Owen M Siggs; Moin A Saleem; Tracy O' Brien; Katie Frith; John B Ziegler; A Richard Kitching; Agnes B Fogo; Billy G Hudson; Vadim Pedchenko Journal: Front Immunol Date: 2019-11-14 Impact factor: 7.561